Press Releases
PUBLICATIONS | NEWS | EVENTS
11.6.24
Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced that members of its management team will participate in one-on-one meetings at the Jefferies London Healthcare Conference taking place November 19–21, 2024. Read More
7.16.24
Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced it will host a virtual KOL webinar on Tuesday, July 30, 2024, at 11:00 AM ET. To register for the webinar, click here. Read More
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced completion of enrollment in its ongoing pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301. Topline data is expected to be available in the second half of 2025. If positive, the results are expected to serve as the foundation for a New Drug Application submission to the U.S. Food and Drug Administration (FDA) and other drug regulatory agencies. Read More
6.11.24
Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the treatment of reperfusion injury, today announced its agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) amendment, enabling the company to expedite its planned Phase 3 study interim analysis. The company also announced its receipt of a notice of “intention to grant” its FDY-5301 patent application from the European Patent Office (EPO), allowing for the expansion of FDY-5301’s protection across the European Union (EU) into 2035.
1.4.24
5.10.22
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular (CV) death and heart failure in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous intervention (PCI). The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration.
12.27.21
Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack
Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life changing critical illness, announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology. Data from the study – known as Iocyte AMI – demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage.
10.14.21
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
Faraday announced the enrollment of its first patient in a Phase 2 study of FDY-5301 (“Iocyte ICU”). FDY-5301 is an elemental reducing agent being developed by the company for the prevention and treatment of ICU-acquired weakness (ICUAW) and other muscle related conditions.
4.13.21
Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol
Actimed Therapeutics Ltd., a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announced a license agreement for S-oxprenolol to Faraday Pharmaceuticals, Inc., a biopharmaceutical company focused on improving outcomes of critical illnesses by reducing the loss of cardiac and skeletal muscle function. S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed.
Read More
3.25.21
Faraday Pharmaceuticals Reaches Special Protocol Agreement with the FDA for its Phase 3 Clinical Trial of FDY-5301 in AMI Reperfusion Injury
SPA Agreement Reached with FDA on Protocol Design and Statistical Approach for Phase 3 FDY-5301 Cardiovascular Outcomes Trial
11.19.19
Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack
Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of small molecules for critical care medicine, today announced top-line results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following ST elevation myocardial infarction (STEMI). These data demonstrated that the treatment was well tolerated, with encouraging signals of efficacy in reducing cardiac damage. Results were presented in an oral presentation at the American Heart Association (AHA) Scientific Sessions 2019.
11.12.19
Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019
Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced that top-line results from its Phase 2 trial of FDY-5301 will be presented at the American Heart Association (AHA) Scientific Sessions 2019 taking place November 16-18, 2019 in Philadelphia, PA.
9.23.16
Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301
Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.
9.3.15
Faraday Pharmaceuticals Announces the Appointment of Dr. Stephen A. Hill as Chief Executive Officer
Faraday Pharmaceuticals today announced the appointment of Stephen A. Hill, M.D., as Chief Executive Officer.
7.8.14
Faraday Pharmaceuticals® Announces Series A Financing
Faraday Pharmaceuticals today announced it has been funded by a Series A purchase of preferred shares.
PUBLICATIONS | NEWS | EVENTS